share_log

SciSparc | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Feb 12 16:31
Summary by Moomoo AI
SciSparc Ltd., a foreign private issuer, reported on February 12, 2024, that it received a termination notice from Dekel Pharmaceuticals Ltd. on February 5, 2024, effectively ending the license agreement between the two companies. The agreement, originally signed on May 20, 2015, and subsequently amended, granted SciSparc an exclusive, worldwide license to certain Dekel technology. Dekel alleges that SciSparc breached material contractual obligations by failing to provide required reports on the licensed products. SciSparc disputes these allegations and plans to defend itself vigorously while assessing the potential impact on its business. The termination and ongoing dispute may have implications for SciSparc's operations and its relationship with Dekel.
SciSparc Ltd., a foreign private issuer, reported on February 12, 2024, that it received a termination notice from Dekel Pharmaceuticals Ltd. on February 5, 2024, effectively ending the license agreement between the two companies. The agreement, originally signed on May 20, 2015, and subsequently amended, granted SciSparc an exclusive, worldwide license to certain Dekel technology. Dekel alleges that SciSparc breached material contractual obligations by failing to provide required reports on the licensed products. SciSparc disputes these allegations and plans to defend itself vigorously while assessing the potential impact on its business. The termination and ongoing dispute may have implications for SciSparc's operations and its relationship with Dekel.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more